A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (Suzhou) Co. Ltd.
First Affiliated Hospital of Guangxi Medical University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Fudan University
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Suzhou Abogen Biosciences Co., Ltd.
Akeso
M.D. Anderson Cancer Center
Second Affiliated Hospital, School of Medicine, Zhejiang University
Peking Union Medical College Hospital
The First Affiliated Hospital with Nanjing Medical University
TJ Biopharma Co., Ltd.
Ruijin Hospital
First Affiliated Hospital of Zhejiang University
Zhongda Hospital
Guangdong Association of Clinical Trials
Sun Yat-sen University
Jiangsu Cancer Institute & Hospital
Sun Yat-sen University
Sichuan University
Hebei Medical University Fourth Hospital
The First Affiliated Hospital with Nanjing Medical University
Peking Union Medical College Hospital
Fujian Haixi Pharmaceuticals Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University
Peking University People's Hospital
Laekna Limited
Henan Cancer Hospital
Fudan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The First Affiliated Hospital with Nanjing Medical University
Jinzhou Medical University
Sun Yat-sen University
M.D. Anderson Cancer Center
Jiangsu Simcere Pharmaceutical Co., Ltd.
Jiangsu Cancer Institute & Hospital
Sun Yat-sen University
Shandong Cancer Hospital and Institute
Tongji Hospital
Henan Cancer Hospital
Tongji Hospital
Innovent Biologics (Suzhou) Co. Ltd.
Shandong Cancer Hospital and Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fudan University
Ruijin Hospital
Sun Yat-sen University
Sun Yat-sen University
Sun Yat-sen University